David Cameron
0000-0002-2717-7979
Publication & Citation Trends
Publications
0 total
Abstract P2-08-21: ELEGANT: Elacestrant versus standard endocrine therapy in women & men with node-positive, estrogen receptor-positive, HER2-negative, early breast cancer with high risk of recurrence in a global, multicenter, randomized, open-label phase 3 study
Cited by 0
Semantic Scholar
Patient-reported outcomes from DESTINY-Breast04: trastuzumab deruxtecan versus physician’s choice of chemotherapy in patients with HER2-low mBC OA
Cited by 10
Semantic Scholar
Machine learning-based spatial characterization of tumor-immune microenvironment in the EORTC 10994/BIG 1-00 early breast cancer trial OA
Cited by 5
Semantic Scholar
Abstract RF3-07: ROSCO: Response to Optimal Selection of neoadjuvant Chemotherapy in Operable breast cancer: Randomised phase III, stratified biomarker trial of neoadjuvant 5-Fluorouracil,Epirubicin & Cyclophosphamide vs Docetaxel & Cyclophosphamide chemotherapy
Cited by 0
Semantic Scholar
Molecular and clinical analyses of gene fusions identify therapeutic targets in paired primary and metastatic breast cancer from the AURORA program (BIG 14-01).
Cited by 0
Semantic Scholar
Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial
Cited by 17
Semantic Scholar
Abstract CT255: ELEGANT: Elacestrant versus standard endocrine therapy (ET) in women and men with node-positive, estrogen receptor-positive (ER+), HER2-negative (HER2-), early breast cancer (eBC) with high risk of recurrence in a global, multicenter, randomized, open-label phase 3 study
Cited by 0
Semantic Scholar
Adjuvant Atezolizumab for Early Triple-Negative Breast Cancer: The ALEXANDRA/IMpassion030 Randomized Clinical Trial.
Cited by 31
Semantic Scholar
Research Topics
Breast Cancer Treatment Studies
(340)
HER2/EGFR in Cancer Research
(260)
Advanced Breast Cancer Therapies
(235)
Cancer Treatment and Pharmacology
(219)
Estrogen and related hormone effects
(73)
Affiliations
Brighton and Sussex Medical School
Université Paris-Sud
Boston University
Ontario Institute for Cancer Research
Champalimaud Foundation